Our interests lie at the interface of chemistry and biology with particular focuses on structure-based drug design, bacterial signaling and regulation, chemical cross-linking development, and polymorphism in pharmaceutical co-crystals.
Research Areas
Research & Development of Active Pharmaceutical Ingredients (API)
Our research projects mainly focused on synthetic organic chemistry which is directly connected to the Pharmaceutical industry. These ongoing projects involve the design and synthesis of small molecules followed by biological evaluation. Our group contributed to many challenging research projects which provided us with a solid foundation in drug discovery, which includes rational drug design, multi-step synthetic organic chemistry, biochemistry, and pharmacology. We are currently working on the synthesis of a diverse class of heterocyclic compound libraries and developing efficient, economical and greener alternatives involving transition metal-catalyzed C-C bond formation, C-N bond cleavage, Lewis acid mediated C-C, C-O and C-N bond formation. Also, we are working in the field of development of drugs via organocatalysis.
Previous
Next
Chem. Soc. Rev., 2024.; Cellular Signalling., 2024.; Journal of Heterocyclic chemistry., 2024; Tetrahedron Lett.,2024; Chemistry Select., 2024, ; Sustainability & Circularity NOW., 2024.; Arkivoc., 2024.; Org. Biomol. Chem., 2024.; Org. Biomol. Chem., 2024. ; J. Org. Chem., 2024. ; Org. Biomol. Chem., 2024.; Asian J. Org. Chem., 2024.; J. Org. Chem., 2024, 5337–5352 ;Bioorganic Chemistry.,2024,107257; American Journal of Heterocyclic Chemistry., 2024.; Eur. J. Org. Chem., 2024, e202301263 ; J. Mol. Struct., 2024, 136920.; Chem Comm., 2024, 416-419.; Chemistry Select., 2023; Che. Eur. J., 2023; Tetrahedron Lett. 2023, 128, 154714; Org. Biomol. Chem., 2023,21, 5521-5526; Org. Biomol. Chem., 2023,21, 5419-5423; Org. Biomol. Chem., 2023,21, 5944-5948; Org. Biomol. Chem., 2023,21, 5176-5180; Asian Journal of Organic Chemistry, 2023, 12, 7; Tetrahedron Lett. 2023, 123, 154547; Green chemistry, 2023, 25, 3034-3039; J. Mol. Struct., 2023, 1279, 134995;Tetrahedron Lett. 2022, 154289; J. Mol. Struct. 2022, 134760; Synthesis. 2022; Synlett. 2022, 01; Chemistry Select. 2022, 7(40); J. Mol. Struct. 2022, 1273, 134280; J. Mol. Struct. 2022, 1273; Chemical Science 2018, 9, 2290–2294; Biotechnology and bioengineering, 2018, 115, 1355-1360; Physical Chemistry Chemical Physics, 2018, 20, 6159–6166; Bioorg. Med. Chem. Lett. 2017, 27, 2967-2973; Chem. Commun. 2017, 53, 3842-3845; ACS Chem. Biol. 2016, 11, 1265-1270; ChemBioChem., 2016, 17, 825-835. 134273; Tetrahedron., 2022, Chemistry Select., 2021, 6, 7408; RSC Adv., 2021, 11, 27950.
X-ray Crystallography, Polymorphism and Pharmaceutical cocrystals
Crystal engineering principles are amenable to improve the physico-chemical properties of the materials, especially in the pharmaceutical industry useful to improve the properties of the drug molecule such as solubility, dissolution rate and bioavilability via the formation of salts, cocrystals, solvates, hydrates and screening of polymorphs etc. without modifying the chemical bonds. Therefore, to further strengthen the field, our research group applied these principles which exist in the crystal engineering were employed to alter the solubility and dissolution properties of solid forms.
Previous
Next
RSC Mechanochemistry.,2024.; Cryst. Growth Des.,2024; Bioorganic Chemistry.,2024; Cryst Eng Comm., 2024; Eur. Polym. J., 2024.; Cryst Eng Comm.,2024, 248-260.;Colloids and Surfaces A: Physicochemical and Engineering Aspects., 2024, 132835; Cryst Eng Comm.,2024, D3CE01130E; Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2024, 682, 132835; J. Mol. Struct, 2023, 1292, 136086; Chem Comm., 2023, 59, 4640-4643; Cryst Eng Comm., 2023, 25, 1874-1883; Results in Chemistry. 2023, 5, 100748; Cryst Eng Comm., 2023, 25, 513-524; Cryst Eng Comm. 2022, 24,7387-7393; Opt. Quantum Electron 2021, 53,197; J. Mol. Struct. 2022, 1269, 133746; Cryst. Growth Des. 2021, 21, 2, 735–747.